Promising New Tools for Targeting p53 Mutant Cancers: Humoral and Cell-Based Immunotherapies

Transcription factor and oncosuppressor protein p53 is considered as one of the most promising molecular targets that remains a high-hanging fruit in cancer therapy. gene encoding the p53 protein is known to be the most frequently mutated gene in human cancers. The loss of transcriptional functions...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in immunology 2021-08, Vol.12, p.707734-707734
Main Authors: Chasov, Vitaly, Zaripov, Mikhail, Mirgayazova, Regina, Khadiullina, Raniya, Zmievskaya, Ekaterina, Ganeeva, Irina, Valiullina, Aigul, Rizvanov, Albert, Bulatov, Emil
Format: Article
Language:English
Subjects:
Animals
Humans
Immunology
Immunotherapy - methods
Mutation
neoantigen
Neoplasms - genetics
Neoplasms - immunology
p53
T cell
T cell receptor
T cell receptor mimic antibody
Tumor Suppressor Protein p53 - genetics
Tumor Suppressor Protein p53 - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Transcription factor and oncosuppressor protein p53 is considered as one of the most promising molecular targets that remains a high-hanging fruit in cancer therapy. gene encoding the p53 protein is known to be the most frequently mutated gene in human cancers. The loss of transcriptional functions caused by mutations in p53 protein leads to deactivation of intrinsic tumor suppressive responses associated with wild-type (WT) p53 and acquisition of new pro-oncogenic properties such as enhanced cell proliferation, metastasis and chemoresistance. Hotspot mutations of p53 are often immunogenic and elicit intratumoral T cell responses to mutant p53 neoantigens, thus suggesting this protein as an attractive candidate for targeted anti-cancer immunotherapies. In this review we discuss the possible use of p53 antigens as molecular targets in immunotherapy, including the application of T cell receptor mimic (TCRm) monoclonal antibodies (mAbs) as a novel powerful approach.
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2021.707734